News sentiment analysis powered by sentiment-insight.com
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript November 14, 2023. Capricor has raised approximately $145 million in equity capital, in totality throughout our company's history.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript August 7, 2023. All lines are in a listen-only mode. Following the presentation we’ll conduct a question-and-answer session.
Capricor: Q2 Earnings Snapshot Capricor Therapeutics Inc. (CAPR) reported a loss of $7.4 million in its second quarter. The biotechnology company posted revenue of $3.9 million in the period.
The past five years for Capricor Therapeutics (NASDAQ:CAPR) investors has not been profitable Capricor Therapeutics, Inc. (NASDAQ:CAPR) share price dropped 67% in the last half decade. The share price decline continued over the last week, dropping some 6.5%. Let's see if the longer term performance of the company has been in line with the underlying business' progress.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares Could Be 27% Above Their Intrinsic Value Estimate Capricor Therapeutics' share price signals that it might be 27% overvalued. Analyst price target for CAPR is US$15.00, which is 372% above our fair value estimate. Using the most recent financial data, we'll take a look at whether the stock is fairly priced.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript March 15, 2023. All participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
Capricor: Q4 Earnings Snapshot Capricor Therapeutics Inc. (CAPR) reported a loss of $7.7 million in its fourth quarter. The biotechnology company posted revenue of $959,900 in the period. For the year, the company reported that its loss widened to $29 million.
Capricor: Q4 Earnings Snapshot Capricor Therapeutics Inc. (CAPR) reported a loss of $7.7 million in its fourth quarter. The biotechnology company posted revenue of $959,900 in the period. In the final minutes of trading on Wednesday, the company's shares hit $4.47.
Capricor: Q4 Earnings Snapshot Capricor Therapeutics Inc. (CAPR) reported a loss of $7.7 million in its fourth quarter. The biotechnology company posted revenue of $959,900 in the period. For the year, the company reported that its loss widened to $29 million.
Sign Up
